Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.
about
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study.The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid TumoursManagement of patients treated with pertuzumab in the Australian clinical practice setting.Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer.Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients.Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer.The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.The effects of advanced age and serum α1 -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients.Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.Combination of Nexrutine and docetaxel suppresses NFκB-mediated activation of c-FLIP.Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.
P2860
Q31036511-435E50AD-AB26-4A95-A3AD-273537603C5EQ33738990-4A3C96BF-EE82-40A6-B6C9-C7D6CAF4DAFCQ35810550-A8B97FEB-9B31-4D95-BA1A-F5598AE40BFBQ36142491-26FA98A7-4933-4E6E-851B-EF2F879AFB1AQ36619606-4F1CB905-26CA-40BC-881C-FC0C1ED3E01BQ36622084-72711524-705F-4ACE-B2EC-5FD8442FD7ACQ37000818-2A19E632-0F44-43F6-8876-E6F192A0F50CQ38850594-1E372379-AE22-4B8C-A1F1-6021B22E336AQ39209358-05BFC710-6E28-459B-A105-70CEBD206838Q39266043-A2EB412E-41F4-4BB7-9E11-AB210441403CQ39317847-E63BC7B2-98BD-43B3-AC0B-EFE11E4E2C5CQ39701080-7F517AF8-F304-489B-AE77-EC346999F1FDQ40222201-F18286B4-E421-41DD-9023-EEDB3C30F04DQ42656439-44716AFA-A456-4A96-B0A0-1694E72F76F1Q47094540-DE0F0E45-9F99-414B-BDCC-3D554B768DBAQ47712403-EA5C09FB-17C9-4D26-B4D9-B344DBA718BAQ48171505-A04D11D7-E29F-4B48-A7F2-4007A70D0A45Q55279322-1B13A05D-84A8-4B4F-A6CD-FE399BAD949E
P2860
Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacokinetics, dynamics and ...... differs from the Western dose.
@ast
Pharmacokinetics, dynamics and ...... differs from the Western dose.
@en
type
label
Pharmacokinetics, dynamics and ...... differs from the Western dose.
@ast
Pharmacokinetics, dynamics and ...... differs from the Western dose.
@en
prefLabel
Pharmacokinetics, dynamics and ...... differs from the Western dose.
@ast
Pharmacokinetics, dynamics and ...... differs from the Western dose.
@en
P2860
P356
P1433
P1476
Pharmacokinetics, dynamics and ...... differs from the Western dose.
@en
P2093
Hirotsugu Kenmotsu
Yusuke Tanigawara
P2860
P304
P356
10.1111/CAS.12647
P577
2015-03-25T00:00:00Z
2015-05-01T00:00:00Z